Ignite Creation Date:
2025-12-25 @ 4:30 AM
Ignite Modification Date:
2026-02-22 @ 6:46 PM
Study NCT ID:
NCT03791918
Status:
WITHDRAWN
Last Update Posted:
2019-05-02
First Post:
2019-01-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006528', 'term': 'Carcinoma, Hepatocellular'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008107', 'term': 'Liver Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C531958', 'term': 'lenvatinib'}, {'id': 'C000711728', 'term': 'spartalizumab'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}, {'id': 'D004621', 'term': 'Embolization, Therapeutic'}], 'ancestors': [{'id': 'D006489', 'term': 'Hemostatic Techniques'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D060205', 'term': 'Therapeutic Occlusion'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}}, 'statusModule': {'whyStopped': 'No participants enrolled', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2019-01-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-01', 'completionDateStruct': {'date': '2022-01-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-04-30', 'studyFirstSubmitDate': '2019-01-01', 'studyFirstSubmitQcDate': '2019-01-01', 'lastUpdatePostDateStruct': {'date': '2019-05-02', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-01-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-01-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall survival', 'timeFrame': '24 months'}], 'secondaryOutcomes': [{'measure': 'Time to progression', 'timeFrame': '24 months'}, {'measure': 'Adverse Events', 'timeFrame': '24 months'}, {'measure': 'Progression free survival', 'timeFrame': '24 months'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Hepatocellular Carcinoma', 'Lenvatinib', 'PD-1 Antibody', 'TACE'], 'conditions': ['Hepatocellular Carcinoma']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria', 'detailedDescription': 'Transarterial chemoembolization (TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients. While a number of studies demonstrate poor effect of TACE for patients with hepatocellular carcinoma staged BCLC A/B especially for those with tumor beyond up-to-seven criteria. Recently, Lenvatinib was proved non-inferior to sorafenib in overall survival in advanced hepatocellular carcinoma, and Programmed Cell Death Protein-1 (PD-1) antibody was effective and tolerable in patients with advanced hepatocellular carcinoma. No study has evaluated the efficacy and safety of lenvatinib plus PD-1 antibody in intermediate-stage HCC. Thus, the investigators carried out this prospective randomized control to demonstrate the superiority of lenvatinib combined with PD-1 antibody over TACE.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)\n* Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria.\n* Barcelona clinic liver cancer-stage B\n* Beyond up-to-seven criteria (hepatocellular carcinomas with seven as the sum of the size of the largest tumor \\[in cm\\] and the number of tumors)\n* Eastern Cooperative Oncology Group performance status of 0 to 1\n* No Cirrhosis or cirrhotic status of Child-Pugh class A only\n* Not applicable for transarterial chemoembolization, surgical resection, and local ablative therapy.\n* The following laboratory parameters:\n\nPlatelet count ≥ 75,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/ L Serum albumin ≥ 30 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \\>1,500/mm3\n\n• Ability to understand the protocol and to agree to and sign a written informed consent document\n\nExclusion Criteria:\n\n* Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy\n* Known history of HIV\n* History of organ allograft\n* Known or suspected allergy to the investigational agents or any agent given in association with this trial.\n* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\n* Evidence of bleeding diathesis.\n* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.\n* Known central nervous system tumors including metastatic brain disease'}, 'identificationModule': {'nctId': 'NCT03791918', 'briefTitle': 'Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria', 'organization': {'class': 'OTHER', 'fullName': 'Sun Yat-sen University'}, 'officialTitle': 'Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Antibody Versus Transarterial Chemoembolization for Intermediate-stage Hepatocellular Carcinoma Beyond Up-to-seven Criteria', 'orgStudyIdInfo': {'id': 'HCC-S065'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Lenvatinib Plus PD-1', 'description': "Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.", 'interventionNames': ['Drug: Lenvatinib', 'Drug: PD-1 antibody']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'TACE', 'description': 'Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).', 'interventionNames': ['Procedure: TACE', 'Drug: TACE Drug Protocol']}], 'interventions': [{'name': 'Lenvatinib', 'type': 'DRUG', 'otherNames': ['E7080, Lenvima'], 'description': '12 mg (or 8 mg) once daily (QD) oral dosing.', 'armGroupLabels': ['Lenvatinib Plus PD-1']}, {'name': 'PD-1 antibody', 'type': 'DRUG', 'otherNames': ['Programmed cell death 1 antibody'], 'description': '3mg/kg intravenously every 2 weeks', 'armGroupLabels': ['Lenvatinib Plus PD-1']}, {'name': 'TACE', 'type': 'PROCEDURE', 'otherNames': ['Transarterial chemoembolization'], 'description': 'A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.', 'armGroupLabels': ['TACE']}, {'name': 'TACE Drug Protocol', 'type': 'DRUG', 'otherNames': ['Drugs for transarterial chemotherapy and embolization'], 'description': 'lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)', 'armGroupLabels': ['TACE']}]}, 'contactsLocationsModule': {'locations': [{'zip': '510060', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Cancer Center Sun Yat-sen University', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '510620', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': "Guangzhou Twelfth People 's Hospita", 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '529300', 'city': 'Kaiping', 'state': 'Guangdong', 'country': 'China', 'facility': 'Kaiping Central Hospital', 'geoPoint': {'lat': 22.572, 'lon': 113.88578}}], 'overallOfficials': [{'name': 'Ming Shi, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Sun Yat-sen University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sun Yat-sen University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Kaiping Central Hospital', 'class': 'OTHER'}, {'name': "Guangzhou No.12 People's Hospital", 'class': 'OTHER_GOV'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Clinical Professor', 'investigatorFullName': 'Shi Ming', 'investigatorAffiliation': 'Sun Yat-sen University'}}}}